News
Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update
Pfizer's US$6 billion licensing deal with 3SBio has boosted market sentiment on Chinese biotech and pharmaceutical companies, sending shares in the sector higher. 3SBio's shares surged 32% to 19.18 Hong Kong dollars,
Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the pipeline, following a major trial setback this ...
Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...
Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...
Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...
Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...
The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID ...
The MoU underscores a shared commitment to strengthening Abu Dhabi’s position as a global hub for healthcare innovation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback